OptiBiotix Health (LON: OPTI) plans to spin off its ProBiotix Health subsidiary on the Aquis Stock Exchange. ProBiotix develops probiotics for treating cardiovascular disease and is expected to join the market on 31 March. OptiBiotix will retain a stake and transfer other ProBiotix shares to its own shareholders.
Peterhouse will be the corporate adviser. A pre-money valuation of £22.5m is anticipated.
The distribution of ProBiotix shares to OptiBiotix shareholders has an ex-dividend date of 24 March. The shareholders will receive 35%-37% of ProBiotix, but they will not be able to...
